CSAT Solved Papers/ 2023/Q63

2023 CSAT — Q63

Verbal Reading comprehension 2.5 marks Hard

Passage

Pharmaceutical patents grant protection to the patentee for the duration of the patent term. The patentees enjoy the liberty to determine the prices of medicines, which is time-limited to the period of monopoly, but could be unaffordable to the public. Such patent protection offered to the patentees is believed to benefit the public over the longer term through innovations and research and development (R&D), although it comes at a cost, in the nature of higher prices for the patented medicine. The patent regime and price protection — through a legally validated high price for the medicine during the currency of the patent — provide the patentee with a legitimate mechanism to get returns on the costs incurred in innovation and research.

Based on the above passage, the following assumptions have been made:

  1. Patent protection given to patentees puts a huge burden on public’s purchasing power in accessing patented medicines.

  2. Dependence on other countries for pharmaceutical products is a huge burden for developing and poor countries.

  3. Providing medicines to the public at affordable prices is a key goal during the public health policy design in many countries.

  4. Governments need to find an appropriate balance between the rights of patentees and the requirements of the patients.

Which of the above assumptions are valid?

  1. A 1 and 2
  2. B 1 and 4 Answer
  3. C 3 and 4
  4. D 2 and 3

Thinking pathway

Locate. On a four-statement valid-assumption question, fix the passage’s actual content. This passage is about pharmaceutical patents: patentees set prices during the monopoly term; those prices “could be unaffordable to the public”; patent protection is believed to benefit the public long-term via R&D, “although it comes at a cost” of higher prices; the regime gives the patentee “a legitimate mechanism to get returns” on innovation. The tension is affordability for the public vs returns for the innovator — and nothing else.

Test (run the actor/entity check first — it does the work here). Statement 1 — “patent protection burdens the public’s purchasing power”: restates “unaffordable to the public” + “higher prices for the patented medicine.” Same entities (patentees, public, price), same mechanism. VALID. Statement 4 — “government must balance patentees’ rights and patients’ requirements”: this is the passage’s own tension (legitimate returns vs affordability), fairly attributed to a policy actor. VALID. Statement 2 — “dependence on other countries… burden for developing and poor countries”: neither other-country dependence nor poor/developing countries appears anywhere — an actor the passage never names. INVALID. Statement 3 — “key goal during public-health policy design in many countries”: neither policy-design nor “many countries” is in the passage — again, an actor/scope the passage never names. INVALID.

Eliminate by anatomy. Options containing 2 (a, d) or 3 (c, d) bring in something the passage doesn’t — globally true pharma-policy claims that this single passage never makes. Strip every option with an added entity and only “1 and 4” survives. The transferable rule: a tightly scoped passage assumes only within its own actors; a statement that widens the frame to “other countries / many countries / poor countries” has left the text. Key: (b).

Evidence in the text

Statement 1 — “The patentees enjoy the liberty to determine the prices of medicines… but could be unaffordable to the public” and “higher prices for the patented medicine” → patent protection burdens the public’s purchasing power: VALID (direct restatement, same entities/mechanism). Statement 4 — the passage’s frame is a legitimate mechanism for patentees to recoup R&D costs versus prices the public may not afford, i.e. a balance government must strike: VALID (fair inference of the passage’s own tension). Statement 2 crosses the ENTITY boundary — “other countries,” “developing and poor countries” are nowhere in the passage → INVALID. Statement 3 crosses the ENTITY boundary — “public health policy design,” “many countries” are nowhere in the passage → INVALID. Valid = 1 and 4 → (b).

Worked rationale

The passage: patentees price patented medicines during the monopoly, possibly unaffordably; the regime is defended as a legitimate way to recoup R&D, at the cost of higher prices.

  • Statement 1 — patent protection burdens public purchasing power. Restates “could be unaffordable to the public” and “higher prices.” Valid.
  • Statement 2 — dependence on other countries burdens developing/poor countries. No other-country dependence, no poor/developing countries in the passage. Invalid (adds entity).
  • Statement 3 — affordable medicine is a key goal in public-health policy design in many countries. No policy-design, no “many countries.” Invalid (adds entity).
  • Statement 4 — governments must balance patentees’ rights and patients’ needs. The passage’s own tension between returns-on-R&D and affordability. Valid.

Valid = 1 and 4. Answer: (b) 1 and 4.

Why the other options miss

  • A
    brings in something the passage doesn’t: keeps the valid Statement 1 but adds Statement 2’s other-country dependence, a real-world pharma concern the passage never raises.
  • C
    brings in something the passage doesn’t: keeps the valid Statement 4 but adds Statement 3’s “policy design in many countries,” widening a single-frame passage to a global one.
  • D
    half right, half wrong: both statements are plausible global truths and both are off-passage; the pairing punishes a reader who scores by world-knowledge instead of text.

Specialist insight

The two invalid statements are both true things about pharmaceutical policy in general — dependence on imports burdens poor countries; affordability is a real policy goal worldwide. That is exactly why they trap: the aspirant who reasons from what they know about global health policy waves them in. The passage, though, is narrow — it talks only about the patentee, the public, prices, and the R&D-vs-affordability balance. The entity boundary is the scalpel: point to the passage word for “other countries” or “many countries” and there is none. Valid = the two statements (1, 4) that stay inside that narrow frame. Answer (b).

The trap, in one line

Statements 2 and 3 are true global pharma-policy claims the narrow passage never makes (added entities); the valid pair restates the passage's own affordability-vs-returns balance — (b).

← All 2023 CSAT questions